Johnson & Johnson Study Shows Tremfya is the First and Only IL-23 Inhibitor to Demonstrate Efficacy in Perianal Fistulizing Crohn's Disease
May 06, 2026
May 06, 2026
RARITAN, New Jersey, May 6 -- Johnson and Johnson Innovative Medicine issued the following news release on May 5, 2026:
* * *
Johnson & Johnson study shows TREMFYA(R) (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
TREMFYA(R) demonstrated significantly higher rates of combined fistula remission - complete external closure of draining fistulas and absence of fluid collection on MRI - . . .
* * *
Johnson & Johnson study shows TREMFYA(R) (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
TREMFYA(R) demonstrated significantly higher rates of combined fistula remission - complete external closure of draining fistulas and absence of fluid collection on MRI - . . .